Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Nephrology
Volume 2017, Article ID 1372859, 8 pages
https://doi.org/10.1155/2017/1372859
Case Report

Kinetics of Rituximab Excretion into Urine and Peritoneal Fluid in Two Patients with Nephrotic Syndrome

1Department of Nephrology, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany
2Department of Hospital Pharmacy, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany
3Department of Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany

Correspondence should be addressed to Klaus Stahl; ed.revonnah-hm@sualk.lhats and Michelle Duong; ed.revonnah-hm@ellehcim.gnoud

Received 13 November 2016; Revised 26 December 2016; Accepted 28 December 2016; Published 24 January 2017

Academic Editor: Kandai Nozu

Copyright © 2017 Klaus Stahl et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. M. Gürcan, D. B. Keskin, J. N. H. Stern, M. A. Nitzberg, H. Shekhani, and A. R. Ahmed, “A review of the current use of rituximab in autoimmune diseases,” International Immunopharmacology, vol. 9, no. 1, pp. 10–25, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. G. L. Plosker and D. P. Figgitt, “Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia,” Drugs, vol. 63, no. 8, pp. 803–843, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. G. M. Keating, “Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large b-cell lymphoma,” Drugs, vol. 70, no. 11, pp. 1445–1476, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. V. Guigonis, A. Dallocchio, V. Baudouin et al., “Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases,” Pediatric Nephrology, vol. 23, no. 8, pp. 1269–1279, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Prytula, K. Iijima, K. Kamei et al., “Rituximab in refractory nephrotic syndrome,” Pediatric Nephrology, vol. 25, no. 3, pp. 461–468, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Ravan, A. Magnasco, A. Edefonti et al., “Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 6, pp. 1308–1315, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Ravani, A. Bonanni, R. Rossi, G. Caridi, and G. M. Ghiggeri, “Anti-CD20 antibodies for idiopathic nephrotic syndrome in children,” Clinical Journal of the American Society of Nephrology, vol. 11, no. 4, pp. 710–720, 2016. View at Publisher · View at Google Scholar
  8. K. Iijima, D. M. Sako, K. Nozu et al., “Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial,” The Lancet, vol. 384, no. 9950, pp. 1273–1281, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Nakayama, K. Kamei, K. Nozu et al., “Rituximab for refractory focal segmental glomerulosclerosis,” Pediatric Nephrology, vol. 23, no. 3, pp. 481–485, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. U. S. Bayrakci, E. Baskin, H. Sakalli, H. Karakayali, and M. Haberal, “Rituximab for post-transplant recurrences of FSGS,” Pediatric Transplantation, vol. 13, no. 2, pp. 240–243, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Ruggenenti, P. Cravedi, A. Chianca et al., “Rituximab in idiopathic membranous nephropathy,” Journal of the American Society of Nephrology, vol. 23, no. 8, pp. 1416–1425, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Gulati, A. Sinha, S. C. Jordan et al., “Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 12, pp. 2207–2212, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Saadoun, M. Resche-Rigon, D. Sene, L. Perard, A. Karras, and P. Cacoub, “Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis,” Annals of the Rheumatic Diseases, vol. 67, no. 10, pp. 1431–1436, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Saadoun, A. Delluc, J. C. Piette, and P. Cacoub, “Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis,” Current Opinion in Rheumatology, vol. 20, no. 1, pp. 23–28, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. S. De Vita, L. Quartuccio, M. Isola et al., “A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis,” Arthritis and Rheumatism, vol. 64, no. 3, pp. 843–853, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Saadoun, M. R. Rigon, D. Sene et al., “Rituximab plus Peg-interferon-α/ribavirin compared with Peg-interferon-α/ribavirin in hepatitis C-related mixed cryoglobulinemia,” Blood, vol. 116, no. 3, pp. 326–334, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Pasquet, F. Combarnous, B. MacGregor et al., “Safety and efficacy of rituximab treatment for vasculitis in hepatitis B virus-associated type II cryoglobulinemia: a case report,” Journal of Medical Case Reports, vol. 6, article 39, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Weinreb, A. Rabinowitz, and P. F. Dellaripa, “Beneficial response to rituximab in refractory Felty syndrome,” Journal of Clinical Rheumatology, vol. 12, no. 1, p. 48, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. V. Lekharaju and C. Chattopadhyay, “Efficacy of rituximab in Felty's syndrome,” Annals of the Rheumatic Diseases, vol. 67, no. 9, article no. 1352, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Salama, U. Schneider, and T. Dörner, “Beneficial response to rituximab in a patient with haemolysis and refractory Felty syndrome,” Annals of the Rheumatic Diseases, vol. 67, no. 6, pp. 894–895, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. C. E. Counsilman, C. M. Jol–van der Zijde, J. Stevens, K. Cransberg, R. G. M. Bredius, and R. N. Sukhai, “Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome,” Pediatric Nephrology, vol. 30, no. 8, pp. 1367–1370, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. C. M. Ng, R. Bruno, D. Combs, and B. Davies, “Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial,” Journal of Clinical Pharmacology, vol. 45, no. 7, pp. 792–801, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Kamei, S. Ito, K. Nozu et al., “Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children,” Pediatric Nephrology, vol. 24, no. 7, pp. 1321–1328, 2009. View at Publisher · View at Google Scholar · View at Scopus